Miyata Y, Mukae Y, Harada J, Matsuda T, Mitsunari K, Matsuo T, Ohba K, Sakai H
Expected outcome: Potentially improved digestive comfort
patients with severe gastrointestinal disease or gastroparesis may not be suitable candidates Hypersensitivity reactions : Including anaphylaxis, have been reported rarely Injection site reactions , including erythema, pruritus, or induration, occur in approximately 25% of patients and are generally self-limited
Glutathione S- transferases
People who already have GLP-1 drugs covered through their Medicare Part D plan or have Type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible
Some professionals claim that this type of synthetic folate may even cause a build-up in the body, leading to toxicity